Variation in PTX3 is associated with primary graft dysfunction after lung transplantation

American Journal of Respiratory and Critical Care Medicine

Volumn 186, Issue 6, 2012, Pages 546-552

  Diamond, Joshua M ^a   Meyer, Nuala J ^a   Feng, Rui ^a   Rushefski, Melanie ^a   Lederer, David J ^a   Kawut, Steven M ^a,b   Lee, James C ^a   Cantu, Edward ^c   Shah, Rupal J ^a   Lama, Vibha N ^c   Bhorade, Sangeeta ^d   Crespo, Maria ^e   Demissie, Ejigayehu ^a   Sonett, Joshua ^f   Wille, Keith ^g   Orens, Jonathan ^h   Weinacker, Ann ⁱ   Weill, David ⁱ   Arcasoy, Selim ^a   Shah, Pali D ^h   Belperio, John A ^j   Wilkes, David ^k   Ware, Lorraine B ^l   Palmer, Scott M ^l   Christie, Jason D ^a   more..

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^c Department of Neurology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

^e UNIVERSITY OF CHICAGO   (United States)

^f UNIVERSITY OF PITTSBURGH   (United States)

^g and Clinical Center   (United States)

^h JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ STANFORD UNIVERSITY   (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

^k INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^l DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

Long pentraxin 3; Lung transplantation; Primary graft dysfunction; Single nucleotide polymorphism

Indexed keywords

PENTRAXIN 3;

ADULT; ALLELE; ARTICLE; CARDIOPULMONARY BYPASS; CLINICAL TRIAL (TOPIC); CONFIDENCE INTERVAL; FEMALE; FIBROSING ALVEOLITIS; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; GRAFT RECIPIENT; HAPLOTYPE; HUMAN; HUMAN TISSUE; INCIDENCE; LOGISTIC REGRESSION ANALYSIS; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); OUTCOME ASSESSMENT; POSTOPERATIVE COMPLICATION; PRIMARY GRAFT DYSFUNCTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RISK; RISK ASSESSMENT; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL SIGNIFICANCE; STRATIFICATION;

C-REACTIVE PROTEIN; COHORT STUDIES; CONFIDENCE INTERVALS; FEMALE; FOLLOW-UP STUDIES; GENETIC ASSOCIATION STUDIES; GENOTYPE; GRAFT REJECTION; GRAFT SURVIVAL; HAPLOTYPES; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; INCIDENCE; LOGISTIC MODELS; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; PRIMARY GRAFT DYSFUNCTION; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SERUM AMYLOID P-COMPONENT; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; TIME FACTORS;

EID: 84866406579     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201204-0692OC     Document Type: Article

References (54)

1. Arcasoy SM, Fisher A, Hachem RR, Scavuzzo M, Ware LB. Report of the ISHLT Working Group on Primary Lung Graft Dysfunction. V. Predictors and outcomes. J Heart Lung Transplant 2005;24:1483-1488.
2. Christie JD, Kotloff RM, Ahya VN, Tino G, Pochettino A, Gaughan C, DeMissie E, Kimmel SE. The effect of primary graft dysfunction on survival after lung transplantation. Am J Respir Crit Care Med 2005;171:1312-1316.
3. Christie JD, Kotloff RM, Pochettino A, Arcasoy SM, Rosengard BR, Landis JR, Kimmel SE. Clinical risk factors for primary graft failure following lung transplantation. Chest 2003;124:1232-1241.
4. Diamond JM, Kawut SM, Lederer DJ, Ahya VN, Kohl B, Sonett J, Palmer SM, Crespo M, Wille K, Lama VN, et al. Elevated plasma Clara cell secretory protein concentration is associated with high-grade primary graft dysfunction. Am J Transplant 2011;11:561-567.
5. Diamond JM, Christie JD. The contribution of airway and lung tissue ischemia to primary graft dysfunction. Curr Opin Organ Transplant 2010;15:552-557.
6. Moreno I, Vicente R, Ramos F, Vicente JL, Barbera M. Determination of interleukin-6 in lung transplantation: association with primary graft dysfunction. Transplant Proc 2007;39:2425-2426.
7. Frantz S, Kobzik L, Kim YD, Fukazawa R, Medzhitov R, Lee RT, Kelly RA. Toll4 (TLR4) expression in cardiac myocytes in normal and failing myocardium. J Clin Invest 1999;104:271-280.
8. Oyama J, Blais C Jr, Liu X, Pu M, Kobzik L, Kelly RA, Bourcier T. Reduced myocardial ischemia-reperfusion injury in Toll-like receptor 4-deficient mice. Circulation 2004;109:784-789.
9. Riad A, Jager S, Sobirey M, Escher F, Yaulema-Riss A, Westermann D, Karatas A, Heimesaat MM, Bereswill S, Dragun D, et al. Toll-like receptor-4 modulates survival by induction of left ventricular remodeling after myocardial infarction in mice. J Immunol 2008;180:6954-6961.
10. Vakeva AP, Agah A, Rollins SA, Matis LA, Li L, Stahl GL. Myocardial infarction and apoptosis after myocardial ischemia and reperfusion: role of the terminal complement components and inhibition by anti-C5 therapy. Circulation 1998;97:2259-2267.
11. Yasojima K, Kilgore KS, Washington RA, Lucchesi BR, McGeer PL. Complement gene expression by rabbit heart: upregulation by ischemia and reperfusion. Circ Res 1998;82:1224-1230.
12. Sorensen TI, Nielsen GG, Andersen PK, Teasdale TW. Genetic and environmental influences on premature death in adult adoptees. N Engl J Med 1988;318:727-732.
13. Garlanda C, Bottazzi B, Bastone A, Mantovani A. Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Annu Rev Immunol 2005;23:337-366.
14. Diamond JM, Lederer DJ, Kawut SM, Lee J, Ahya VN, Bellamy S, Palmer SM, Lama VN, Bhorade S, Crespo M, et al. Elevated plasma long pentraxin-3 levels and primary graft dysfunction after lung transplantation for idiopathic pulmonary fibrosis. Am J Transplant 2011;11:2517-2522.
15. Breviario F, d'Aniello EM, Golay J, Peri G, Bottazzi B, Bairoch A, Saccone S, Marzella R, Predazzi V, Rocchi M, et al. Interleukin-1-inducible genes in endothelial cells: cloning of a new gene related to C-reactive protein and serum amyloid P component. J Biol Chem 1992;267:22190-22197.
16. Lee GW, Lee TH, Vilcek J. TSG-14, a tumor necrosis factor- and IL-1-inducible protein, is a novel member of the pentaxin family of acute phase proteins. J Immunol 1993;150:1804-1812.
17. Mantovani A, Garlanda C, Bottazzi B. Pentraxin 3, a non-redundant soluble pattern recognition receptor involved in innate immunity. Vaccine 2003;21:S43-S47.
18. Ortega-Hernandez OD, Bassi N, Shoenfeld Y, Anaya JM. The long pentraxin 3 and its role in autoimmunity. Semin Arthritis Rheum 2009;39:38-54.
19. Han B, Haitsma JJ, Zhang Y, Bai X, RubachaM, Keshavjee S, Zhang H, Liu M. Long pentraxin PTX3 deficiency worsens LPS-induced acute lung injury. Intensive Care Med 2010;37:334-342.
20. He X, Han B, Bai X, Zhang Y, Cypel M, Mura M, Keshavjee S, Liu M. Ptx3 as a potential biomarker of acute lung injury: supporting evidence from animal experimentation. Intensive Care Med 2010;36:356-364.
21. He X, Han B, Liu M. Long pentraxin 3 in pulmonary infection and acute lung injury. Am J Physiol Lung Cell Mol Physiol 2007;292:L1039-L1049.
22. Mauri T, Coppadoro A, Bellani G, Bombino M, Patroniti N, Peri G, Mantovani A, Pesenti A. Pentraxin 3 in acute respiratory distress syndrome: an early marker of severity. Crit Care Med 2008;36:2302-2308.
23. Muller B, Peri G, Doni A, Torri V, Landmann R, Bottazzi B, Mantovani A. Circulating levels of the long pentraxin PTX3 correlate with severity of infection in critically ill patients. Crit Care Med 2001;29:1404-1407.
24. Wagenaar JF, Goris MG, Gasem MH, Isbandrio B, Moalli F, Mantovani A, Boer KR, Hartskeerl RA, Garlanda C, van Gorp EC. Long pentraxin PTX3 is associated with mortality and disease severity in severe leptospirosis. J Infect 2009;58:425-432.
25. Basile A, Sica A, d'Aniello E, Breviario F, Garrido G, Castellano M, Mantovani A, Introna M. Characterization of the promoter for the human long pentraxin PTX3: role of NF-κB in tumor necrosis factor-α and interleukin-1β regulation. J Biol Chem 1997;272:8172-8178.
26. Diamond JM, Feng R, Meyer NJ, Lederer D, Lee J, Kawut S, Ahya V, Cantu E, Palmer S, Weinacker A, et al. PTX3 polymorphisms are associated with primary graft dysfunction after lung transplantation [abstract]. J Heart Lung Transplant 2011;30:S23.
27. Christie JD, Bellamy S, Ware LB, Lederer D, Hadjiliadis D, Lee J, Robinson N, Localio AR, Wille K, Lama V, et al. Construct validity of the definition of primary graft dysfunction after lung transplantation. J Heart Lung Transplant 2010;29:1231-1239.
28. Christie JD, Robinson N, Ware LB, Plotnick M, De Andrade J, Lama V, Milstone A, Orens J, Weinacker A, Demissie E, et al. Association of protein C and type 1 plasminogen activator inhibitor with primary graft dysfunction. Am J Respir Crit Care Med 2007;175:69-74.
29. Christie JD, Shah CV, Kawut SM, Mangalmurti N, Lederer DJ, Sonett JR, Ahya VN, Palmer SM, Wille K, Lama V, et al. Plasma levels of receptor for advanced glycation end products, blood transfusion, and risk of primary graft dysfunction. Am J Respir Crit Care Med 2009;180:1010-1015.
30. Christie JD, Carby M, Bag R, Corris P, Hertz M, Weill D. Report of the ISHLT Working Group on Primary Lung Graft Dysfunction. II. Definition: a consensus statement of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2005;24:1454-1459.
31. Christie JD, Van Raemdonck D, de Perrot M, Barr M, Keshavjee S, Arcasoy S, Orens J. Report of the ISHLT Working Group on Primary Lung Graft Dysfunction. I. Introduction and methods. J Heart Lung Transplant 2005;24:1451-1453.
32. 1000 Genomes Project Consortium. A map of human genome variation from population-scale sequencing. Nature 2010;467:1061-1073.
33. International HapMap Consortium. The International HapMap Project. Nature 2003;426:789-796.
34. Keating BJ, Tischfield S, Murray SS, Bhangale T, Price TS, Glessner JT, Galver L, Barrett JC, Grant SF, Farlow DN, et al. Concept, design and implementation of a cardiovascular gene-centric 50K SNP array for large-scale genomic association studies. PLoS One 2008;3:e3583.
35. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J, Sklar P, de Bakker PI, Daly MJ, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007;81:559-575.
36. Christie JD, Wurfel MM, Feng R, O'Keefe GE, Bradfield J, Ware LB, Christiani DC, Calfee CS, Cohen MJ, Matthay M, et al. Genome wide association identifies PPFIA1 as a candidate gene for acute lung injury risk following major trauma. PLoS One 2012;7:e28268.
37. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005;21:263-265.
38. Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumenstiel B, Higgins J, DeFelice M, Lochner A, Faggart M, et al. The structure of haplotype blocks in the human genome. Science 2002;296:2225-2229.
39. Cypel M, Yeung JC, Liu M, Anraku M, Chen F, Karolak W, Sato M, Laratta J, Azad S, Madonik M, et al . Normothermic ex vivo lung perfusion in clinical lung transplantation. N Engl J Med 2011;364:1431-1440.
40. Kastelijn EA, van Moorsel CH, Rijkers GT, Ruven HJ, Karthaus V, Kwakkel-van Erp JM, van de Graaf EA, Zanen P, van Kessel DA, Grutters JC, et al. Polymorphisms in innate immunity genes associated with development of bronchiolitis obliterans after lung transplantation. J Heart Lung Transplant 2010;29:665-671.
41. Munster JM, van der Bij W, Breukink MB, van der Steege G, Zuurman MW, Hepkema BG, Verschuuren EA, van Son WJ, Seelen MA. Association between donor MBL promoter haplotype and graft survival and the development of BOS after lung transplantation. Transplantation 2008;86:1857-1863.
42. Palmer SM, Burch LH, Davis RD, Herczyk WF, Howell DN, Reinsmoen NL, Schwartz DA. The role of innate immunity in acute allograft rejection after lung transplantation. Am J Respir Crit Care Med 2003;168:628-632.
43. Palmer SM, Burch LH, Trindade AJ, Davis RD, Herczyk WF, Reinsmoen NL, Schwartz DA. Innate immunity influences long-term outcomes after human lung transplant. Am J Respir Crit Care Med 2005;171:780-785.
44. Palmer SM, Klimecki W, Yu L, Reinsmoen NL, Snyder LD, Ganous TM, Burch L, Schwartz DA. Genetic regulation of rejection and survival following human lung transplantation by the innate immune receptor CD14. Am J Transplant 2007;7:693-699.
45. Chiarini M, Sabelli C, Melotti P, Garlanda C, Savoldi G, Mazza C, Padoan R, Plebani A, Mantovani A, Notarangelo LD, et al. PTX3 genetic variations affect the risk of Pseudomonas aeruginosa airway colonization in cystic fibrosis patients. Genes Immun 2010;11:665-670.
46. Olesen R, Wejse C, Velez DR, Bisseye C, Sodemann M, Aaby P, Rabna P, Worwui A, Chapman H, Diatta M, et al. DC-SIGN (CD209), pentraxin 3 and vitamin D receptor gene variants associate with pulmonary tuberculosis risk in West Africans. Genes Immun 2007;8:456-467.
47. 7 gut-homing integrin during acute infection leads to decreased plasma and gastrointestinal tissue viral loads in simian immunodeficiency virus-infected rhesus macaques. J Immunol 2011;186:1044-1059.
48. Lee KH, Liu YJ, Biswas A, Ogawa C, Kobayashi KS. A novel aminosaccharide compound blocks immune responses by Toll-like receptors and nucleotide-binding domain, leucine-rich repeat proteins. J Biol Chem 2011;286:5727-5735.
49. Shimamoto A, Chong AJ, Yada M, Shomura S, Takayama H, Fleisig AJ, Agnew ML, Hampton CR, Rothnie CL, Spring DJ, et al. Inhibition of Toll-like receptor 4 with eritoran attenuates myocardial ischemia-reperfusion injury. Circulation 2006;114:I270-I274.
50. Barreiro LB, Ben-Ali M, Quach H, Laval G, Patin E, Pickrell JK, Bouchier C, Tichit M, Neyrolles O, Gicquel B, et al. Evolutionary dynamics of human Toll-like receptors and their different contributions to host defense. PLoS Genet 2009;5:e1000562.
51. Ferwerda B, McCall MB, Alonso S, Giamarellos-Bourboulis EJ, Mouktaroudi M, Izagirre N, Syafruddin D, Kibiki G, Cristea T, Hijmans A, et al. TLR4 polymorphisms, infectious diseases, and evolutionary pressure during migration of modern humans. Proc Natl Acad Sci USA 2007;104:16645-16650.
52. Ma X, Liu Y, Gowen BB, Graviss EA, Clark AG, Musser JM. Full-exon resequencing reveals Toll-like receptor variants contribute to human susceptibility to tuberculosis disease. PLoS One 2007;2:e1318.
53. Plantinga TS, Ioana M, Alonso S, Izagirre N, Hervella M, Joosten LA, van der Meer JW, de la Rua C, Netea MG. The evolutionary history of TLR4 polymorphisms in Europe. J Innate Immun 2012;4:168-175.
54. Vasseur E, Patin E, Laval G, Pajon S, Fornarino S, Crouau-Roy B, Quintana-Murci L. The selective footprints of viral pressures at the human RIG-I-like receptor family. Hum Mol Genet 2011;20:4462-4474.